Evidence map›Paper›PMID 42567965›Full record

ArticleInternational journal of clinical oncology2026

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

Tetsuro Ochi, Shinichi Makita, Anna Hiratsuka, Risa Nishiyama, Kimiteru Ito, Akiko Miyagi Maeshima, Wataru Takeda, Noriko Iwaki, Suguru Fukuhara, Wataru Munakata and 1 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Tetsuro OchiDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shinichi MakitaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. smakita@ncc.go.jp.ORCID http://orcid.org/0000-0001-6609-8088
Anna HiratsukaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Risa NishiyamaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kimiteru ItoDepartment of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Akiko Miyagi MaeshimaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Wataru TakedaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Noriko IwakiDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile clinical data on anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) have been established, data specifically focusing on high-grade B-cell lymphoma (HGBCL) remain limited.

methodsTo evaluate the efficacy of CAR T-cell therapy for HGBCL, we conducted a single-center retrospective study of patients with R/R HGBCL who received CAR T-cell therapy at our institution between March 2022 and October 2024.

resultsThis study included 15 patients with R/R HGBCL treated with CAR T-cell therapy (10 with axicabtagene ciloleucel and 5 with lisocabtagene maraleucel). The median age at CAR T-cell infusion was 62 years (range, 39-76 years). Eleven patients (73.3%) were refractory to first-line therapy and 11 (73.3%) had MYC and BCL2 rearrangements. High-grade morphology was observed in nine patients (60.0%). Nine patients (60.0%) received CAR T-cell therapy as second-line treatment. The best overall response rate was 80.0%, with a complete response rate of 66.7%. At a median follow-up of 18.5 months (range, 1.3-26.0 months), the 1-year progression-free survival (PFS) rate was 40.0%. In univariate analysis, high-grade morphology was associated with inferior PFS (HR 5.09; 95% CI 1.46-17.73, p = 0.019), whereas high lactate dehydrogenase level and high metabolic tumor volume at lymphodepletion, number of prior lines of chemotherapy and MYC and BCL2 rearrangements were not significantly associated with PFS.

conclusionThe efficacy of CAR T-cell therapy in patients with R/R HGBCL remains suboptimal. High-grade morphology may help identify patients at particularly high risk of poor outcomes following CAR T-cell therapy.

Indexed as

CAR T-cell therapyHigh-grade B-cell lymphomaImmunotherapy

Identifiers

PMID42567965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.